Researchers from Australia and the USA have developed a new class of antimalarial components that can effectively combat parasites.

In preclinical trials, the compounds were effective against various types of malaria parasites, including the deadly Plasmodium falciparum, and at several stages of its life cycle.. The compounds target a previously unexplored parasite trait that can solve the problem of its resistance to drugs. This problem has recently become increasingly relevant.. Researchers hope drugs based on these compounds will enter Phase 1 clinical trials soon..

“In preclinical trials, compound WM382 inhibited the growth of the malaria parasite in the carrier and prevented its transmission back to the mosquito. These results show that this class of compounds is very promising from the point of view of developing a new drug for the treatment of malaria. We hope that drugs based on this compound will be submitted for clinical trials in phase 1, ”says Professor Alan Couman, an international malaria expert and deputy director of the Walter and Eliza Hall Medical Research Institute.

https: // www. medikforum. com /.

Keywords:.